|
|
|
| Clinical value of the levels of serum pregnancy-associated plasma protein A and placental growth factor of pregnant women during the first trimester of pregnancy for evaluating their preeclampsia |
| Jiaozhou Center Hospital, Qingdao, Shandong Province, 266300 |
|
|
|
|
Abstract To explore the application value of the levels of serum pregnancy-associated plasma protein A (PAPP-A) and placental growth factor (PlGF) of pregnant women during the first trimester of pregnancy for evaluating their preeclampsia (PE). Methods: The clinical data of 80 pregnant women with PE in study group who were registered in hospital during the first trimester of pregnancy and treated until delivery from October 2018 to November 2021 were analyzed retrospectively. The women in the study group were divided 35 women with severe PE in group A and 45 women with mild PE in group B. The clinical data of 84 healthy pregnant women who had pregnancy examination and were followed up until delivery in control group during the same period were also analyzed retrospectively. The levels of serum PAPP-A and PlGF and the urine protein value (24h urine protein) during the first trimester of pregnancy (11-13 gestational weeks), and the values of blood pressure (systolic blood pressure and diastolic blood pressure) during the third trimester of pregnancy of the women were compared among these groups. Pearson correlation coefficient was used to analyze the correlation between the levels of serum PAPP-A and PlGF of the women during the first trimester of pregnancy and their urine protein value (24h urine protein) during the first trimester of pregnancy and the values of blood pressure (systolic blood pressure and diastolic blood pressure) during the third trimester of pregnancy. The predictive efficacy of the serum PAPP-A and PlGF levels during the first trimester of pregnancy of the women for their PE was analyzed by receiver operating characteristic (ROC) curve. Results: The levels of serum PAPP-A (25.91±2.64 ng/ml) and PlGF (18.07±2.93μg/L) of the women in the study group were significantly lower than those (28.15±3.42 ng/ml and 21.77±4.35μg/L) of the women in the control group. The 24h urine protein quantification level and the values of the systolic blood pressure and diastolic blood pressure of the women in the study group were significantly higher than those of the women in the control group. The levels of serum PAPP-A and PLGF of the women in group A were significantly lower than those of the women in group B (all P<0.05). Correlation analysis showed that the serum PAPP-A and PlGF levels of the women with PE were negatively correlated with their 24-hour urinary protein quantitative level and systolic blood pressure and diastolic blood pressure values. ROC curve analysis showed that the sensitivity, the specificity and the area under the curve (AUC) of the PAPP-A level of the pregnant women during the first trimester of pregnancy for predicting their PE occurrence were 74.3%, 66.7% and 0.676, respectively. The sensitivity, the specificity and the AUC of the PlGF level of the pregnant women during the first trimester of pregnancy for predicting their PE occurrence were 60.0%, 68.9% and 0.671, respectively (P<0.05). Conclusion: The levels of PAPP-A and PlGF of the pregnant women with PE during the first trimester of pregnancy are lower than those of the healthy pregnant women, and which of the women decrease with their PE severity. The levels of PAPP-A and PlGF of the pregnant women during the first trimester of pregnancy have certain predictive values for their PE occurrence.
|
|
|
|
|
|
|
|
|
